← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Heparin group
reviparin
B01AB08
Forms & Strengths
- Injection: 1,432 IU anti-Xa / 0.25 mL
- Injection: 3,570 IU anti-Xa / 0.25 mL
- Injection: 6,428 IU anti-Xa / 0.5 mL
Adult Dosing
- Prevention of deep vein thrombosis in general surgery: 1,432 IU anti-Xa subcutaneously once daily, starting 2 hours before surgery
- Prevention of deep vein thrombosis in orthopedic surgery: 3,570 IU anti-Xa subcutaneously once daily
- Treatment of deep vein thrombosis: 1,785 to 3,570 IU anti-Xa subcutaneously twice daily based on body weight
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Prophylaxis of venous thromboembolism in surgical patients
- Treatment of acute deep vein thrombosis
Mechanism of Action
- Low molecular weight heparin with antithrombotic activity
- Potentiates the inhibition of coagulation factor Xa and thrombin (Factor IIa) by antithrombin III
Contraindications
- Known hypersensitivity to reviparin, heparin, or pork products
- Active major bleeding or conditions with high risk of hemorrhage
- History of heparin-induced thrombocytopenia (HIT)
- Acute bacterial endocarditis
- Severe, uncontrolled hypertension
Adverse Reactions
- Hemorrhage and bleeding complications
- Injection site hematoma, pain, and irritation
- Thrombocytopenia (including heparin-induced thrombocytopenia)
- Elevated liver transaminases
- Allergic reactions including anaphylactoid symptoms
Drug Interactions
- Increased risk of bleeding with concomitant antiplatelet agents (e.g., aspirin, clopidogrel)
- Increased bleeding risk with NSAIDs and systemic glucocorticoids
- Additive anticoagulant effects with oral anticoagulants (e.g., warfarin)
Curated Content: Needs Vetting Before Put to Clinical Use